Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.59 |
| ▸ | CA1 | P00915 | 4/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | XBP1 | P17861 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217652 | 0.89 | CA2 (0.63) | CA2CA1MAPK1FAAHATM | |
| SCHEMBL23581684 | 0.89 | CA2 (0.63) | CA2CA1MAPK1FAAHATM | |
| SCHEMBL246299 | 0.84 | FAAH (0.59) | CA2CA1MAPK1FAAHALDH1A1 | |
| SCHEMBL1834730 | 0.84 | CA2 (0.58) | CA2CA1MAPK1FAAHATM | |
| SCHEMBL28627724 | 0.84 | CA2 (0.58) | CA2CA1MAPK1FAAHATM | |
| SCHEMBL7223074 | 0.84 | FAAH (0.59) | CA2CA1MAPK1FAAHALDH1A1 | |
| SCHEMBL1377605 | 0.84 | FAAH (0.59) | CA2CA1MAPK1FAAHALDH1A1 | |
| SCHEMBL149487 | 0.84 | CA2 (0.58) | CA2CA1MAPK1FAAHATM | |
| SCHEMBL27803012 | 0.84 | FAAH (0.59) | CA2CA1MAPK1FAAHALDH1A1 | |
| SCHEMBL4286403 | 0.84 | CA2 (0.61) | CA2CA1MAPK1FAAHATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10751337-B2 | Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders | Ocugen, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| EP-3569223-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | Intratus, Inc. (US) | 2019-11-20 | — | — | EP | disclosed |
| EP-2493474-B1 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | INTRATUS INC (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20180221278-A1 | PRSUSTAINED RELEASE OPTHALMIC FORMUATION AND METHODS FOR USING THE SAME | Ocugen, Inc. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180153885-A1 | PRESERVATIVE FREE OCULAR COMPOSITIONS AND METHODS FOR USING THE SAME FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-06-07 | — | — | US | disclosed |
| US-9877964-B2 | Methods and compositions for treating dry eye disease and other eye disorders | Ocugen, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-3261620-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | The Board of Trustees of the University of Illionis (US) | 2018-01-03 | — | — | EP | disclosed |
| US-20170189396-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2017-07-06 | — | — | US | disclosed |
| US-9597328-B2 | Methods and compositions for treating dry eye disease and other eye disorders | Ocugen, Inc. (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016138049-A1 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE DISEASE AND OTHER EYE DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-09-01 | — | — | WO | disclosed |
| EP-2493475-A2 | METHODS AND COSMETIC PREPARATIONS FOR THE SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO THE EYE | Intratus, Inc. (US) | 2012-09-05 | — | — | EP | disclosed |
| US-8101654-B2 | Percutaneously absorptive ophthalmic preparation comprising olopatadine | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2012-01-24 | — | — | US | disclosed |
| WO-2011053801-A2 | METHODS AND COSMETIC PREPARATIONS FOR THE SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO THE EYE | INTRATUS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011053792-A2 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | INTRATUS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20110104206-A1 | METHODS AND COMPOSITIONS FOR SUSTAINED DELIVERY OF DRUGS | INTRATUS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20110104083-A1 | METHODS AND COSMETIC PREPARATIONS FOR THE SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO THE EYE | INTRATUS, INC. | 2011-05-05 | — | — | US | disclosed |
| US-20090209632-A1 | Percutaneously Absorptive Ophthalmic Preparation Comprising Olopatadine | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090143359-A1 | Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1901708-A1 | PERCUTANEOUSLY ABSORPTIVE OPHTHALMIC PREPARATION COMPRISING OLOPATADINE | Senju Pharmaceutical Co., Ltd. (JP) | 2008-03-26 | — | — | EP | disclosed |
| WO-2007007863-A1 | PERCUTANEOUSLY ABSORPTIVE OPHTHALMIC PREPARATION COMPRISING OLOPATADINE | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-18 | — | — | WO | disclosed |